Allspring Global Investments Holdings LLC Purchases 20948 Shares in 4D Molecular Therapeutics,
February 1, 2023
Trending News ☀️
4D ($NASDAQ:FDMT)MT is a clinical-stage biopharmaceutical company that specializes in the development of transformative gene and cell therapies. They are driven to improve patient outcomes, and have been creating innovative medicines that target rare diseases and unmet medical needs. 4DMT has several programs in development that are focused on the treatment of genetic diseases. This includes a vector development platform for gene therapy, a gene therapy product for a rare form of Stargardt’s disease, and a gene therapy product for cystinosis. In addition to these programs, 4DMT has entered into several collaborations with leading pharmaceutical and biotechnology companies to develop novel therapeutics. By investing in 4DMT, Allspring Global Investments Holdings LLC is hoping to capitalize on the company’s growing portfolio of products and technologies.
The company is well-positioned to continue developing its gene and cell therapies, as well as enter into strategic partnerships with other biotechnology companies. With this investment, Allspring is also hoping to benefit from 4DMT’s expertise in gene therapy and their innovative scientific platform. This investment by Allspring Global Investments Holdings LLC is an exciting move that further validates the potential of 4D Molecular Therapeutics, Inc. It is clear that 4DMT is well-positioned to continue developing its innovative gene and cell therapies, as well as enter into strategic partnerships with other biotechnology companies. With this investment, Allspring is hoping to benefit from 4DMT’s expertise in gene therapy and their innovative scientific platform.
Price History
Despite the purchase, 4D Molecular Therapeutics, Inc.’s stock opened at $22.6 and closed at $21.3, showing an increase of 0.1% from its previous closing price of $21.3. This news has been met with mostly positive media exposure. 4D Molecular Therapeutics, Inc. is an innovative biotech company that focuses on gene therapy and gene editing. The company works on groundbreaking treatments and technologies to help treat a variety of diseases, such as hereditary blindness, cystic fibrosis and sickle cell disease. The company has made great strides in their cutting-edge research and technology to make these treatments a reality.
The purchase also indicates that Allspring Global Investments Holdings LLC believes that the company can continue to make progress in its treatments. It shows that more investors are recognizing the potential of gene therapy and gene editing and are willing to put their money into the industry. This could lead to more financial support for the development of innovative treatments, which could have a positive impact on people’s lives. If the company can continue to make progress in its treatments, then it could have a positive effect on many people’s lives. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for FDMT. More…
| Total Revenues | Net Income | Net Margin |
| 1.97 | -105.2 | -395.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for FDMT. More…
| Operations | Investing | Financing |
| -86.31 | -13.56 | 117.18 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for FDMT. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 280.16 | 28.72 | 7.76 |
Key Ratios Snapshot
Some of the financial key ratios for FDMT are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.5% | – | -395.5% |
| FCF Margin | ROE | ROA |
| -5159.4% | -25.3% | -23.7% |
VI Analysis
The analysis of 4D MOLECULAR THERAPEUTICS has been made easier with the VI app, which reflects the company’s long term potential. According to the VI Star Chart, 4D MOLECULAR THERAPEUTICS has an intermediate health score of 6/10. This score considers the company’s cashflows and debt, and suggests that 4D MOLECULAR THERAPEUTICS may be able to sustain future operations in times of crisis. 4D MOLECULAR THERAPEUTICS is classified as an ‘elephant’, a type of company that is rich in assets after deducting off liabilities. This makes it an attractive option for investors who are looking for companies with a strong asset base and little risk. The company is strong in asset, but weak in dividend, growth, and profitability, which reduces its attractiveness to some investors. Investors who are looking for a secure investment may be interested in 4D MOLECULAR THERAPEUTICS due to its strong asset base and low risk. However, those who are looking for higher returns may find that other options with better dividend, growth and profitability ratings may provide more attractive returns. Ultimately, it is up to the investor to decide if 4D MOLECULAR THERAPEUTICS is a good investment for them. More…
VI Peers
The company’s proprietary technology platform, Directed Evolution of Nucleic Acids (DENA), enables the directed evolution of highly specific nucleic acid therapeutics. 4D has a strategic collaboration with Genentech, a member of the Roche Group, for the development and commercialization of 4D-122, which is in Phase I clinical trials for the treatment of Duchenne muscular dystrophy (DMD). 4D’s main competitors are Freeline Therapeutics Holdings PLC, BioLine Rx Ltd, and Gossamer Bio Inc. All three companies are engaged in the discovery and development of therapeutics using cutting-edge technology platforms with the aim of bringing innovative treatments to patients with serious diseases.
– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)
Freeline Therapeutics Holdings PLC is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment of hemophilia and other bleeding disorders. The company has a market cap of $49.38 million and a return on equity of -1.18%. Freeline Therapeutics Holdings PLC is headquartered in London, the United Kingdom.
– BioLine Rx Ltd ($NASDAQ:BLRX)
BioLine Rx Ltd is a clinical-stage biopharmaceutical company, which engages in the identification, in-licensing, and development of therapeutics for the treatment of cancer and other therapeutic areas. The company was founded by Philip A. Serlin and Abraham B. Zlotnik on April 21, 2003 and is headquartered in Jerusalem, Israel.
– Gossamer Bio Inc ($NASDAQ:GOSS)
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. The company’s lead product candidate is GB001, an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.
Gossamer Bio Inc has a market cap of $990.28M as of 2022 and a Return on Equity of -1952.91%. The company focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. GB001, the company’s lead product candidate, is an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.
Summary
Media coverage of the purchase has been mostly positive, which is a good sign for those looking to invest in 4D Molecular Therapeutics, Inc. It is important to do further research into the company’s financials and future plans before investing in the company to ensure that it is a good investment.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
